Board of directors
Anders Lundberg
Chairman of the Board (member of the board since 2017)
About:
M.Sc. Mechanical Engineering, KTH, Stockholm, Sweden. Founder and CEO of a telecom equipment supplier recognized by the market and later brought to a successful IPO in 2011 on the MID-CAP list OMX-Nasdaq [TRMO:Transmode]
Other assignments:
AJ Lundberg Kapitalförvaltning AB; Board member
Sollentunafastigheter 2 AB; Deputy board member
Sollentunahem AB; Deputy board member
Independent in relation to Prostatype Genomics, its senior management and major shareholders.
Holdings in the Company:
See Insiders information
Håkan Englund
Board Member since 2019
About:
Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden. CEO and owner, JDS Invest. More than 30 years of operational and investment experience from life science and health care industry with focus on commercialization and business development. Håkan has held several leading management positions at Pharmacia Biotech and Phadia and has during his career developed extensive national and international relevant networks.
Other assignments:
Antrad Medical AB; Board member
SecureAppbox AB; Chairman of the Board
Independent in relation to Prostatype Genomics, its senior management and major shareholders.
Holdings in the Company:
See Insiders information
Dr. Michael Häggman
Board Member since 2018
About:
M.D, Ph.D. associate professor, department of Urology, Akademiska University Hospital, Uppsala, Sweden. More than 30 years of experience practicing as urologist with an extensive national and international network among urologists.
Other assignments:
Skrotum Kommanditbolag; General partner
Kardinaltalet AB; Deputy board member
Independent in relation to Prostatype Genomics, its senior management and major shareholders.
Holdings in the Company:
See Insiders information
Jörgen Dahlström
Board member since 2023.
About:
Holds a Ph.D. in Immunology and a M.Sc. in Biochemistry from Uppsala University and an Executive MBA. Jörgen is the CEO of Mercodia, a Swedish based Life Science company and has more than 25 years’ experience from the international Life Science industry. The main focus has been on developing and executing company strategies for commercialization and business growth. He has held several senior leadership positions including CEO of Svar Life Science. Jörgen has an extensive strategic and commercial experience and a wide international network.
Independent in relation to Prostatype Genomics, its senior management and major shareholders
Holdings in the Company:
See Insiders information
Mattias Prage
Board Member since 2022
About:
Lawyer and partner at Advokatfirman Lindahl, specialized in corporate law, financing and commercial contracts.
Independent in relation to Prostatype Genomics, its senior management and major shareholders.
Holdings in the Company:
See Insiders information